AMPLATZER™ Cardiac Plug Observational Post-Approval Study

NCT02954237•Abbott Medical Devices

Summary

The purpose of this study is to observe the safety and effectiveness of the AMPLATZER™ Cardiac Plug (ACP) device in Chinese population indicated for use of AMPLATZER™ Cardiac Plug after its market approval by China FDA (CFDA). This is a prospective, multi-centre, single arm, post approval, observational study. The clinical study will be conducted at up to 35 sites in China. Approximately 343 subjects will be enrolled in this study. The total study duration is expected to be approximately 7 years. The study population included patients who have non-valvular atrial fibrillation (NVAF) and are contraindicated to long-term oral anticoagulant; or patients who experience stroke or other thromboembolic event despite taking warfarin. Scheduled office visits occur at 45 days (+45 days), 6M (+/- 3 weeks) 12M (+/- 6 weeks) and 24 M(+/- 6 weeks) post procedure; Phone contact follow up visits occur at, 36 M (+/- 6 weeks), 48M (+/- 6 weeks) and 60 M (+/- 6 weeks) post procedures.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient who meets the current indications and per physician discretion for ACP implant
•2. Patient who is ≥ 18 years of age at the time of enrolment
•3. Patient who is able to provide written Informed Consent prior to any study related procedures

Exclusion Criteria

•1. Patient who is unable to comply with the follow-up schedule
•2. Patient with the presence of intracardiac thrombus
•3. Patient with active endocarditis or other infections producing bacteraemia
•4. Patient who has low risk of stroke (CHA2DS2-VASC score is 0 or 1) or low risk of bleeding (HAS-BLED score\<3)
•5. Patient where placement of the device would interfere with any intracardiac or intravascular structures
•6. Patient who is under medical conditions not appropriate to participate in the study in the opinion of the investigator
•7. Patient with LAA anatomy that does not accommodate a device per the sizing guidelines
•8. Patient who has a life expectancy of less than 2 years due to any condition
•9. Patient who are currently participating in a clinical investigation that includes an active treatment arm
•10. Patient who already had a left atrial appendage closure device implanted prior to the study

Locations (6)

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Sir Run Run Shaw Hospital

Zhejiang, Hangzhou, China

Wuhan Asia Heart Hospital

Wuhan, Hubei, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Ningbo First Hospital

Ningbo, Liuting Saint, China

The First Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Key Dates

Start Date

November 14, 2016

Primary Completion Date

January 29, 2021

Completion Date

January 29, 2021

Last Updated

June 24, 2022

Enrollment

ACTUAL participants

Conditions

Non-valvular Atrial Fibrillation (NVAF)

Interventions

AMPLATZER™ Cardiac Plug

DEVICE

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

NCT06606275

End-Stage Kidney Disease (ESKD)Non-valvular Atrial Fibrillation (NVAF)+1 more

View study

COMPLETED

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

NCT05022758

Non-valvular Atrial Fibrillation (NVAF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions